CannBioRx Life Sciences Corp
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical t… Read more
CannBioRx Life Sciences Corp (ATNFW) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.210x
Based on the latest financial reports, CannBioRx Life Sciences Corp (ATNFW) has a cash flow conversion efficiency ratio of -0.210x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.13 Million) by net assets ($5.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CannBioRx Life Sciences Corp - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how CannBioRx Life Sciences Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
CannBioRx Life Sciences Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CannBioRx Life Sciences Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nova Organic PCL
BK:NV
|
-0.013x |
|
C29 Metals Ltd
AU:C29
|
-0.213x |
|
Guard Therapeutics International AB
ST:GUARD
|
-1.630x |
|
Guided Therapeutics Inc
OTCQB:GTHP
|
0.049x |
|
Gayatri Highways Limited
NSE:GAYAHWS
|
1.168x |
|
Auric Resources Corp.
V:RES
|
-0.061x |
|
Fusion Fuel Green PLC
NASDAQ:HTOO
|
-0.275x |
|
Tangelo Games Corp
V:GEL
|
-0.675x |
Annual Cash Flow Conversion Efficiency for CannBioRx Life Sciences Corp (2017–2024)
The table below shows the annual cash flow conversion efficiency of CannBioRx Life Sciences Corp from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.25 Million | $-1.48 Million | -0.160x | -100.19% |
| 2023-12-31 | $-127.73K | $-10.92 Million | 85.508x | +8098.28% |
| 2022-12-31 | $11.34 Million | $-12.13 Million | -1.069x | -985.73% |
| 2021-12-31 | $39.32 Million | $-3.87 Million | -0.098x | +22.98% |
| 2020-12-31 | $30.29 Million | $-3.87 Million | -0.128x | -48.58% |
| 2019-12-31 | $38.57 Million | $-3.32 Million | -0.086x | -1141.34% |
| 2018-12-31 | $113.87 Million | $-789.23K | -0.007x | -57.23% |
| 2017-12-31 | $112.83 Million | $-497.36K | -0.004x | -- |